Biolevate is a Paris-based AI-native technology company building an evidence-grade agentic platform for regulated life sciences operations. Founded in 2024 by former Dataiku engineers and AI researchers, the company automates complex document-heavy workflows across the pharmaceutical value chain — including clinical protocol co-authoring, clinical study reports, regulatory dossier preparation, HTA submissions, pharmacovigilance (PSUR authoring, safety signal triage), and systematic literature reviews. Every AI-generated output is grounded in cited source evidence and paired with a full audit-ready Evidence Trail, keeping human experts in the review loop at every step.

The platform, now branded under the ELISE/OCEAN technology stack, combines NLP, computer vision, knowledge graphs, and specialized AI agents to serve pharmaceutical, medical device, cosmetics, and nutrition companies. It can run up to 100,000 agents concurrently and claims a 16× acceleration in systematic literature reviews and an 80% efficiency gain in regulatory intelligence workflows. Customers include Sanofi, with strategic partnerships also established with NVIDIA (BioNeMo Agent Toolkit) and Microsoft.

Biolevate raised a €6 million seed round in November 2024 led by EQT Ventures, followed by a €30 million Series A in September 2026 co-led by RAISE France and Orange Ventures, bringing total disclosed funding to €36 million. The company has grown to approximately 50 employees and opened a Boston office to support US expansion into the pharmaceutical industry hub. It holds ISO/IEC 27001 and 27701 certifications and has filed seven patent applications, two of which have been submitted in Europe.